Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Name | Title | Since | Age |
|---|---|---|---|
| Amit D. Munshi | Chairman & Interim CEO | 2026 | 58 |
| Eric Forquenot de La Fortelle | Independent Director | - | - |
| Christine Petit | Chair of Scientific Advisory Board | 2018 | - |
| Julien Miara | Director | 2019 | 43 |
| Khalil Barrage | Director | 2023 | 61 |
| Cédric Moreau | Director | 2019 | 49 |
| Hernán López-Schier | Member of Scientific Advisory Board | 2020 | - |
| Paul Avan | Member of Scientific Advisory Board | 2020 | - |
| Diane Lazard | Member of Scientific Advisory Board | 2020 | - |
| Robert J. Dow | Member of Scientific Advisory Board | 2020 | 75 |
| Alain Fischer | Member of Scientific Advisory Board | 2020 | - |
| Aniz Girach | Independent Director | 2022 | 59 |
| Natalie Brittenham Berner | Director | 2023 | 36 |
| Florian Nicolas Christian Reinaud | Board Observer | 2023 | 53 |
| Federico Mingozzi | Independent Director | 2024 | 52 |